A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)-Reference-Cited by-同舟云学术

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

Published:2021-04-02 Issue:6 Volume:30 Page:473-480
ISSN:1057-0829
Container-title:Journal of Glaucoma
language:en
Short-container-title:

Author:

Olander Kenneth W.,Sato Michelle A.,Abrams Marc A.,Jerkins Gary W.,Lu Fenghe,Dinh Phillip,Odani-Kawabata Noriko,Chabi Almira,Shams Naveed K.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology

Reference23 articles.

1. Definition of glaucoma: clinical and experimental concepts;Casson;Clin Exp Ophthalmol,2012

2. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis;Tham;Ophthalmology,2014

3. Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients;El Hajj Moussa;J Ophthalmol,2018

4. Pharmacotherapy of glaucoma;Schmidl;J Ocul Pharmacol Ther,2015

5. European Glaucoma Society terminology and guidelines for glaucoma (4th Ed)–chapter 3: treatment principles and options;Br J Ophthalmol,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current trends and prospects of the local antihypertensive drugs development for the glaucoma treatment;Russian Ophthalmological Journal;2024-07-02

2. Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3);American Journal of Ophthalmology;2024-07

3. Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial;Clinical Ophthalmology;2024-07

4. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma;Japanese Journal of Ophthalmology;2024-04-08

5. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug;Current Opinion in Pharmacology;2024-02